Welcome to our dedicated page for Steris Plc SEC filings (Ticker: STE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings for STERIS plc (NYSE: STE) provide detailed regulatory information about this Ireland-incorporated medical technology company, which focuses on products and services that support patient care with an emphasis on infection prevention. Through its filings, STERIS discloses financial results, governance decisions, executive transitions and shareholder meeting outcomes, giving investors a structured view of the company’s regulatory history.
Current reports on Form 8-K filed by STERIS include items on Results of Operations and Financial Condition, where the company furnishes press releases announcing quarterly financial results. These filings reference segment performance for Healthcare, Applied Sterilization Technologies (AST) and Life Sciences, and describe the use of non-GAAP measures such as adjusted net income, adjusted earnings per diluted share, free cash flow, organic revenue growth and constant currency organic revenue growth.
Other 8-K filings address Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers, detailing transitions in the Chief Financial Officer role and related compensation and equity arrangements. Filings also summarize matters submitted to a vote of security holders, including the election of directors, appointment and remuneration of auditors, advisory votes on executive compensation and renewals of the Board’s authority to issue shares and opt out of statutory pre-emption rights under Irish law.
On this page, investors can review STERIS’s SEC reports alongside AI-powered summaries that explain the key points of each filing, highlight important sections and clarify technical language. Real-time updates from EDGAR ensure that new Forms 8-K and other reports appear promptly. Users can quickly identify filings related to quarterly earnings (such as 8-Ks furnishing press releases), governance and compensation topics, and other material events that shape STERIS’s financial and corporate profile.
STERIS plc (STE) officer and V.P. & Corporate Treasurer reported option exercises and share sales. On November 18, 2025, the insider exercised an employee stock option for 3,536 ordinary shares at an exercise price of $182.22 per share, then sold shares in several transactions at market prices around the mid-$250s. Reported sales included 3,324 shares at a weighted average price of $257.43, 212 shares at a weighted average price of $258.03, and 1,500 shares at $257.76 per share.
After these transactions, the reporting person beneficially owned 5,695 ordinary shares, including 1,475 restricted shares as of November 18, 2025. The restricted shares are scheduled to vest in installments between June 1, 2026 and June 5, 2028, and the reported stock option is now fully vested with no remaining balance.
STERIS plc (STE) insider activity is disclosed in a Form 144 notice indicating an intention to sell 5,036 ordinary shares. The planned sale, through Charles Schwab & Co., Inc., has an aggregate market value of $1,297,033 and is expected to occur around 11/18/2025 on the NYSE. The company reports 98,147,009 shares outstanding, so this planned sale represents a small portion of total shares.
The securities to be sold were acquired mainly through equity compensation from STERIS plc, including an employee stock option exercise of 3,536 shares on 11/18/2025 via a broker-assisted cashless exercise and several restricted stock lapses between 05/31/2023 and 10/01/2024. The notice also reports that the same holder sold 3,204 shares of STERIS on 08/20/2025 for gross proceeds of $798,560 in the past three months.
STERIS plc (STE) Form 4: The company’s Senior Vice President, General Counsel and Secretary exercised 15,000 employee stock options at $69.72 per share on 11/11/2025 and sold 15,000 ordinary shares the same day at a weighted average price of $265.14 (range $265.00–$265.95). Following these transactions, the officer directly owned 33,669 shares as of 11/11/2025. Of these, 8,511 are restricted, with scheduled lapses through June 2028.
STERIS plc received a Form 144 notice for a proposed sale of 15,000 Ordinary shares. The filing lists an aggregate market value of $3,977,050 and an approximate sale date of 11/11/2025. The designated broker is Charles Schwab & Co., Inc., and the shares are to be sold on the NYSE.
The shares were acquired on 11/11/2025 via an employee stock option exercise with a broker payment for cashless exercise. This notice reflects an intended disposition by a holder under Rule 144.
STERIS plc reported stronger quarterly results for the three months ended September 30, 2025. Revenue rose to $1,460.3 million from $1,328.9 million as Healthcare delivered $1,033.8 million, Applied Sterilization Technologies $281.5 million, and Life Sciences $145.0 million. Operating income increased to $265.8 million from $219.7 million, with net income attributable to shareholders of $191.9 million (diluted EPS $1.94) versus $150.0 million ($1.51) a year ago. The effective tax rate was 23.9%.
Through six months, operating cash flow was $707.8 million, funding capital spending of $180.1 million and supporting cash balances of $319.2 million. Total debt declined to $1,897.3 million from $2,043.7 million. The company repurchased 0.4 million shares for $100.0 million and paid dividends of $1.20 per share year-to-date. Remaining performance obligations were $1,926.4 million, with approximately 53% expected to be recognized within one year.
STERIS plc furnished an 8-K to announce it issued a press release with financial results for the quarter ended September 30, 2025, which is its fiscal 2026 second quarter. The press release is attached as Exhibit 99.1.
The information under Item 2.02, including Exhibit 99.1, is being furnished to the SEC, not deemed “filed” under Section 18 of the Exchange Act, and is not incorporated by reference into Securities Act filings.
Massachusetts Financial Services Company filed an amended Schedule 13G reporting its beneficial ownership in STERIS plc (STE).
MFS reported beneficial ownership of 4,846,124 shares of STERIS common stock, representing 4.9% of the class as of the reported event date. The firm disclosed sole voting power over 4,674,537 shares and sole dispositive power over 4,846,124 shares, with no shared voting or shared dispositive power.
The filing certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of STERIS.
Director and CEO Daniel A. Carestio reported a small open-market sale of 159 ordinary shares on 10/06/2025 at a price of $241.82 per share, leaving beneficial ownership of 51,096 shares. The filing indicates 33,054 of those shares are restricted with scheduled lapses: 06/01/2026 (4,308), 06/02/2026 (2,369), 06/03/2026 (5,937), 06/04/2026 (4,283), 06/03/2027 (5,937), 06/04/2027 (4,283), and 06/05/2028 (5,937). The form is filed individually and indicates the transaction was reported under a Rule 10b5-1 plan.
STERIS plc filed a Form 144 reporting a proposed sale of 159 ordinary shares through Charles Schwab & Co., Inc. on 10/06/2025 with an aggregate market value of $38,449. The securities were acquired on 10/01/2025 by lapse of restricted stock granted as equity compensation. The filing lists 98,490,606 shares outstanding, so the 159 shares represent an immaterial fraction of the company's outstanding stock. No other sales in the past three months are reported and the filer affirms they are not aware of undisclosed material adverse information.
John Adam Zangerle, Senior Vice President, General Counsel and Secretary of STERIS plc (STE), reported that 202 restricted ordinary shares awarded on October 1, 2021 vested on October 1, 2025. Of those vested shares, 91 were withheld to satisfy tax withholding obligations, recorded as a disposition. After the transaction, Mr. Zangerle beneficially owns 33,669 ordinary shares. The filing notes 8,511 ordinary shares remain restricted with staggered lapse dates between June 1, 2026 and June 5, 2028. The Form 4 was signed by an authorized representative on October 3, 2025.